Drugs / IK-595
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06270082 | Dec 2023 → Sep 2025 | colorectal cancer, malignant glioma, malignant pancreatic neoplasm, melanoma +2 | Ikena Oncology | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IK-595 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06270082 ↗ |
| Action | Inhibit | “a dual mitogen-activated protein kinase kinase (MEK)/ RAF kinase inhibitor” NCT06270082 ↗ |
| Modality | Other / unclassified | “IK-595, a MEK/RAF molecular glue” NCT06270082 ↗ |
| Route | Oral | “administered orally (PO)” NCT06270082 ↗ |